TY - JOUR
T1 - The utility of 99mTc-mebrofenin hepatobiliary scintigraphy with SPECT/CT for selective internal radiation therapy in hepatocellular carcinoma
AU - Labeur, Tim A
AU - Cieslak, Kasia P
AU - Van Gulik, Thomas M
AU - Takkenberg, R Bart
AU - van der Velden, Sandra
AU - Lam, Marnix G E H
AU - Klümpen, Heinz-Josef
AU - Bennink, Roel J
AU - van Delden, Otto M
N1 - Funding Information:
R.B.T.: served as a speaker for Gore WL, Bayer, and Norgine. He is member of the advisory board for Gilead and Norgine. He has received grants from the Netherlands Organisation for Health Research and Development (ZonMw) and The Netherlands Society for Gastroenterology (NVGE). M.G.E.H.L. is consultant for BTG and Terumo. The department of Radiology and Nuclear Medicine of the UMC Utrecht receives royalties and research support from Quirem Medical/Terumo. H.-J.K. is member of the advisory board for Ipsen and Sirtex, and his institution received an unrestricted research grant from Bayer (no grant numbers apply). O.M.V.D. served as consultant for Cook Medical. For the remaining authors, there are no conflicts of interests.
Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/8
Y1 - 2020/8
N2 - Background Studies assessing the impact of selective internal radiation therapy (SIRT) on the regional liver function in patients with hepatocellular carcinoma (HCC) are sparse. This study assessed the changes in total and regional liver function using hepatobiliary scintigraphy (HBS) and investigated the utility of HBS to predict post-SIRT liver dysfunction. Methods Patients treated with SIRT for HCC between 2011 and 2019, underwent
99mTc-mebrofenin HBS with single-photon emission computed tomography/computed tomography (SPECT/CT) before and 6 weeks after SIRT. The corrected mebrofenin uptake rate (cMUR) and corresponding volume was measured in the total liver, and in treated and nontreated liver regions. Patients with and without post-SIRT liver dysfunction were compared. Results A total of 29 patients, all Child-Pugh-A and mostly intermediate (72%) stage HCC were included in this study. Due to SIRT, the cMUR
totaldeclined from 5.8 to 4.5%/min/m
2(P < 0.001). Twenty-two patients underwent a lobar SIRT, which induced a decline in cMUR (2.9-1.7%/min/m
2, P < 0.001) and volume (1228-1101, P = 0.002) of the treated liver region, without a change in cMUR (2.4-2.0%/min/m
2, P = 0.808) or volume (632-644 mL, P = 0.661) of the contralateral nontreated lobe. There were no significant pre-SIRT differences in total or regional cMUR or volume between patients with and without post-SIRT liver dysfunction. Conclusion In patients treated with SIRT for HCC, HBS accurately identified changes in total and regional liver function and may have a complementary role to personalize lobar or selective SIRT. In this pilot study, there were no pre-SIRT differences in cMUR or volume to aid in predicting post-SIRT liver dysfunction.
AB - Background Studies assessing the impact of selective internal radiation therapy (SIRT) on the regional liver function in patients with hepatocellular carcinoma (HCC) are sparse. This study assessed the changes in total and regional liver function using hepatobiliary scintigraphy (HBS) and investigated the utility of HBS to predict post-SIRT liver dysfunction. Methods Patients treated with SIRT for HCC between 2011 and 2019, underwent
99mTc-mebrofenin HBS with single-photon emission computed tomography/computed tomography (SPECT/CT) before and 6 weeks after SIRT. The corrected mebrofenin uptake rate (cMUR) and corresponding volume was measured in the total liver, and in treated and nontreated liver regions. Patients with and without post-SIRT liver dysfunction were compared. Results A total of 29 patients, all Child-Pugh-A and mostly intermediate (72%) stage HCC were included in this study. Due to SIRT, the cMUR
totaldeclined from 5.8 to 4.5%/min/m
2(P < 0.001). Twenty-two patients underwent a lobar SIRT, which induced a decline in cMUR (2.9-1.7%/min/m
2, P < 0.001) and volume (1228-1101, P = 0.002) of the treated liver region, without a change in cMUR (2.4-2.0%/min/m
2, P = 0.808) or volume (632-644 mL, P = 0.661) of the contralateral nontreated lobe. There were no significant pre-SIRT differences in total or regional cMUR or volume between patients with and without post-SIRT liver dysfunction. Conclusion In patients treated with SIRT for HCC, HBS accurately identified changes in total and regional liver function and may have a complementary role to personalize lobar or selective SIRT. In this pilot study, there were no pre-SIRT differences in cMUR or volume to aid in predicting post-SIRT liver dysfunction.
KW - hepatobiliary scintigraphy
KW - hepatocellular carcinoma
KW - radioembolization
KW - selective internal radiation therapy
KW - volumetry
UR - https://www.scopus.com/pages/publications/85088268756
U2 - 10.1097/MNM.0000000000001224
DO - 10.1097/MNM.0000000000001224
M3 - Article
C2 - 32649575
SN - 0143-3636
VL - 41
SP - 740
EP - 749
JO - Nuclear Medicine Communications
JF - Nuclear Medicine Communications
IS - 8
ER -